Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients

Antiviral Therapy

Volumn 18, Issue 7, 2013, Pages 841-852

  Pan, Calvin Q ^a   Hu, Ke Qin ^b   Tsai, Naoky ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; NUCLEOSIDE ANALOG; TENOFOVIR;

ASIAN; CAUCASIAN; DRUG RESPONSE; EVIDENCE BASED MEDICINE; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LONG TERM CARE; MEDICAL DECISION MAKING; NONHUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW;

ADENINE; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; ORGANOPHOSPHONATES; TREATMENT OUTCOME;

EID: 84892774701     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/imp2481     Document Type: Review

References (92)

1. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009;27:6550-6557.
2. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204. July 2013. (Accessed November 2013.) Available from http://www.who.int/mediacentre/factsheets/fs204/en
3. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012;56:422-433.
4. Hu KQ, Pan CQ, Goodwin D. Barriers to screening for hepatitis B virus infection in Asian Americans. Dig Dis Sci 2011;56:3163-3171.
5. Chung PW, Suen SH, Chan OK, Lao TH, Leung TY. Awareness and knowledge of hepatitis B infection and prevention and the use of hepatitis B vaccination in the Hong Kong adult Chinese population. Chin Med J (Engl) 2012;125:422-427.
6. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology 2011;54:91-100.
7. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
8. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-893.
9. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t) ide therapy: a systematic review. J Hepatol 2010;53:348-356.
10. Tong MJ, Pan CQ, Hann HW, et al. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci 2011;56:3143-3162.
11. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
12. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-561.
13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
14. Cao GW Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009;15:5761-5769.
15. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-352.
16. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134-1143.
17. Ni YH, Chang MH, Wang KJ, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004;127:1733-1738.
18. Chen CH, Lee CM, Lu SN, et al. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol 2005;43:6000-6006.
19. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124:327-334.
20. Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 2006;193:1258-1265.
21. Malik A, Asim M. Ligase chain reaction as a modality for the detection of point mutation in precore region of HBV related HCC cases. Hepatology International 2011;5:308.
22. Pan C, Zeng Z, Hu K. Clinical features of chronic hepatitis B (CHB) in treatment naive Asian patients with positive HBeAg and co-existing precore and/or basal core promoter (PC/BCP) mutations. Gastroenterology 2009;136 Suppl 1:A-865.
23. Pan C, Chan YF, Bansal R. Treatment response to peginterferon alpha-2A (PEG-IFN) in HBeAg positive chronic hepatitis B (CHB) patients with co-existing precore and/or basal core promoter mutations. Hepatology 2009;50:514A.
24. Wu IC, Shiffman ML, Tong MJ, et al. Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. Clin Infect Dis 2008;47:1305-1311.
25. Chang T, Shiffman ML, Tang M, et al. Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB). Gastroenterology 2006;130:A-846.
26. Yao G, Xu D, Wang B, et al. A phase II study in China of the safety and antiviral activity of entecavir in adults with chronic hepatitis B infection. Hepatology 2003;38 Suppl 4:711A.
27. Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009;104:1940-1946.
28. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-806.
29. Chaung KT, Ha NB, Trinh HN, et al. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012;46:865-870.
30. Zhang JM, Xu Y, Wang XY, et al. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtypespecific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis 2007;44:1161-1169.
31. Yao G, Chen C, Lu W, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int 2007;1:365-372.
32. Shindo M, Chayama K, Mochida S, et al. Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, doubleblind, Phase II clinical trial. Hepatol Int 2009;3:445-452.
33. Kobashi H, Takaguchi K, Ikeda H, et al. Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: phase II clinical study in Japan. J Gastroenterol Hepatol 2009;24:255-261.
34. Gish RG, Tsai N, Pan C, et al. Efficacy and safety of entecavir in nucleos (t) ide naive asians with HBeAg-positive and -negative chronic hepatitis B: results from studies ETV-022/027. Hepatology 2010;52:561A.
35. Lee SS, Heathcote J, Sievert W, et al. Tenofovir disoproxil fumarate (TDF) versus adefovir in Asians with HBeAgpositive and HBeAg-negative chronic hepatitis B participating in studies 102 and 103. Hepatology 2008;48:746A.
36. Pan C, Chan S, Trink H, et al. Tenofovir disproxil fumarate (TDF) shows similar virological suppression and safety between Asians and non-Asians with chronic hepatitis B (CHB). Hepatol Int 2011;5:130.
37. Yao G, Xu D, Ren H, et al. Three years of continuous treatment with entecavir results in high proportions of Chinese nucleoside-naive patients with undetectable HBV DNA: results from studies ETV-023 and -050. Hepatol Int 2008;2:A162.
38. Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol 2010;52:791-799.
39. Pan CQ, Tong M, Kowdley KV, et al. High Rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10:1047-1050el.
40. Chang TT, Lai CL, Kew YS, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-430.
41. Gane E, Lee SS, Heathcote EJ, et al. Four years efficacy and safety of tenofovir disoproxil fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B, preliminary analysis. Hepatology 2010;52:559A.
42. Gane EJ, Marcellin P, Sievert W, et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection in Asian patients is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011;54:1038A.
43. Marcellin P, Buti M, Gane EJ, et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2012;54:1011A.
44. Hou J, Ren H, Wang Y, et al. Efficacy and safety of entecavir treatment in a heterogenous CHB population in a real-life clinical practice setting in China. Hepatol Int 2011;5:146.
45. Seto WK, Lai CL, Fung J, Yuen JC, Wong DK, Yuen ME Outcome of 4-year treatment of entecavir for treatmentnaive chronic hepatitis B. J Hepatol 2011;54 Suppl 1:S301.
46. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatmentnaive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011;106:1264-1271.
47. Ha NB, Ha NB, Garcia RT, et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci 2011;56:2423-2431.
48. Chan S, Pan C, Bae H, et al. Tenofovir disoproxil fumarate (TDF) demonstrates good efficacy and safety in Asians with chronic hepatitis B (CHB) in real-life settings. Hepatol Int 2011;5:131.
49. Lin B, Ha NB, Liu A, et al. Low incidence of hepatitis B e antigen (HBeAg) seroconversion with oral monotherapy in chronic hepatitis B (CHB) treatment-naive patients at year 1 in clinical practice. Hepatology 2011;54:l045A.
50. Chang TT, Lai CL, Yoon SK, et al. Long-term virologicalal suppression, resistance and histological improvement in nucleos (t) ide-naive Asian chronic hepatitis B patients treated with entecavir in studies ETV-022/-027/-901. Hepatol Int 2011;5:119.
51. Colvin HM, Mitchell AE. A national strategy for prevention and control of hepatitis B and C. Washington DC: National Academies Press 2010.
52. Guan R, Lui HF. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol 2011; doi:10.4061/2011/918017.
53. Henkel AS, Buchman AL. Nutritional support in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 2006;3:202-209.
54. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol 2007;21 Suppl C: 5C-24C.
55. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-182.
56. Cheinquer H, Raptopoulou-Gigi M, Kumar Sarin S, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation: week 96 results. Hepatology International 2011;5:272.
57. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
58. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002;22 Suppl 2:5-13.
59. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011;53:774-780.
60. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
61. Ha NB, Ha NB, Ahmed A, et al. Risk factors for hepatocellular carcinoma among patients with underlying chronic liver disease: a prospective study. Hepatology 2010;52:682A.
62. Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192-1199.
63. Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virologicalal suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral (s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011;60:1109-1116.
64. Jin YJ, Shim JH, Lee HC, et al. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma. J Gastroenterol Hepatol 2011;26:1380-1388.
65. Kobashi H, Miyake Y, Ikeda F, et al. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res 2011;41:405-416.
66. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
67. +/-rtN236T in Asian versus European patients. Heptology 2011;5:1066A.
68. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-2006.
69. Lampertico P, Soffredini R, Vigano M, et al. Effectiveness and safety of tenofovir disproxil fumarate in field practice: a multicentre European cohort study of 302 NUC-naive patients with chronic hepatitis B. J Hepatol 2011;54:S293.
70. Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol 2011;55:1235-1240.
71. Nguyen H-L, Al-Freah A, Joe D. A single centre, large 'real-life' cohort treated with tenfovir versus entecavir: no deterioration in tenofovir cohort over 12 months of thearpy. Hepatology 2012; S4:604A.
72. Duarte-Rojo A, Heathcote EJ. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol 2010;3:107-119.
73. Gara N, Ghany MG, Zhao X, Collins MT, Hoofnagle JH. Phosphate wasting nephropathy in patients with chronic hepatitis B treated with long-term adefovir or tenofovir. Hepatology 2011;54:479A.
74. Tragulpiankit P, Dhana N, Tanwandee T, Kittichaisri K, Sitthimongkhonkarn P. The study of adverse drug reaction of tenofovir in chronic hepatitis B virus infection at Siriraj Hospital, Thailand. Hepatol Int 2011;5:147.
75. Manns MP, Akarca US, Chang TT, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012;11:361-368.
76. Tenney DJ, Pokornoski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol 2009;50 Suppl 1:S10.
77. + and HBeAg-chronic hepatitis B virus infection. Hepatology 2011;54:480A.
78. Gish RG, Chang TT, Lai CL, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010;17:16-22.
79. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011;26 Suppl 1:123-130.
80. Lee H, Hu K, Tonthat S. HBV treatment induced HBsAG seroconversion to anti-HBs in 9 Asian-American patients: experience in a community clinic. Hepatology 2011;54:1034A.
81. Lim SG. Should HBe seroconversion be an endpoint of treatment of chronic hepatitis ? Hepatol Int 2011;5:41.
82. Tseng TC, Liu CJ, Wang CC, et al. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Antivir Ther 2009;14:203-210.
83. Yamaura T, Tanaka E, Matsumoto A, et al. A casecontrol study for early prediction of hepatitis B e antigen seroconversion by hepatitis B virus DNA levels and mutations in the precore region and core promoter. J Med Virol 2003;70:545-552.
84. Yuen MF, Wong DK, Zheng BJ, et al. Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. J Viral Hepat 2007;14:269-275.
85. Zoutendijk R, Sonneveld MJ, Reinders JG, et al. Relationship between precore/base core promoter mutants and serologicalal or virologicalal response in HBeAgpositive chronic hepatitis B treated with nucleos (t) ide analogues. Hepatology 2011;54:1025A.
86. Wong GL, Wong VW, Chan HY, et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther 2012;35:1326-1335.
87. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naive patients with a partial virologicalal response. Hepatology 2011;54:443-451.
88. Sonneveld MJ, Zoutendijk R, Janssen HL. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat 2011;18:449-457.
89. Fung J, Lai CL, Young J, et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011;106:1766-1773.
90. Zoutendijk R, Hansen BE, Van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos (t) ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011;204:415-418.
91. Hutton DW, Brandeau ML, So SK. Doing good with good OR: supporting cost-effective hepatitis B interventions. Interfaces (Providence) 2011;41:289-300.
92. Lok AS, Trink HN, Carosi G, Akarca US, Gadano A. Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos (t) ide-naive patients with chronic hepatitis B (CHB): the BE-LOW study. Hepatology 2012;54:471A.